Drugs / DC vaccines
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06435910 | May 2024 → Jul 2027 expected | plasma cell neoplasm | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC vaccines | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06435910 ↗ |
| Modality | Cell therapy | “The DCvacs are patient's own DCs which are immune modified to present target antigens and to activate anti-cancer immunity.” NCT06435910 ↗ |